TScan Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer treatment, has announced its participation in two upcoming investor conferences:

1. Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on September 5, 2024, at 8:30 a.m. ET at the New York Marriott Marquis.

2. H.C. Wainwright 26th Annual Global Investment Conference: Presentation on September 10, 2024, at 9:00 a.m. ET at the Lotte New York Palace Hotel.

Webcasts of both events will be available on TScan's website under the "Events and Presentations" section, with archived replays accessible for 90 days post-event.

News Market Reaction

-0.88%

1 alert

-0.88% News Effect

On the day this news was published, TCRX declined 0.88%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:

• Morgan Stanley 22^nd Annual Global Healthcare Conference; the fireside chat will be held at the New York Marriott Marquis on Thursday, September 5, 2024 at 8:30 a.m. ET
  
  
• H.C. Wainwright 26^th Annual Global Investment Conference; the presentation will be held at the Lotte New York Palace Hotel on Tuesday, September 10, 2024 at 9:00 a.m. ET
  

Webcasts of the fireside chat and presentation will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcasts will be available on the Company’s website for 90 days following the events.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA Phase 1 heme trial). The Company is also developing TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers.

Contacts

Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com

Maghan Meyers
Argot Partners
212-600-1902
TScan@argotpartners.com

FAQ

When is TScan Therapeutics (TCRX) participating in the Morgan Stanley Global Healthcare Conference?

TScan Therapeutics (TCRX) will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024, at 8:30 a.m. ET.

Where can I watch the webcasts of TScan Therapeutics' (TCRX) investor conference presentations?

Webcasts of TScan Therapeutics' (TCRX) investor conference presentations will be available on the "Events and Presentations" section of the company's website at ir.tscan.com.

What type of therapies is TScan Therapeutics (TCRX) developing?

TScan Therapeutics (TCRX) is developing T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer.

How long will the archived replays of TScan Therapeutics' (TCRX) conference webcasts be available?

Archived replays of TScan Therapeutics' (TCRX) conference webcasts will be available on the company's website for 90 days following the events.